Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Cardiology/Vascular Diseases | Hematology | Family Medicine
Search Medical Condition
Dyslipidemia Clinical Trials
A listing of Dyslipidemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (70) clinical trials
Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of A Study Compound, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects
A clinical research trial to prevent cardiovascular events due to high lipid or cholesterol levels
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia Protocol Number (AMG 145/Evolocumab) 20130287
Receive Evolocumab or Placebo for the treatment of Diabetics with High Cholesterol.
A Study to Evaluate the Efficacy and Safety of Alirocumab versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk Not Adequately Controlled with Maximally Tolerated Statin Therapy
You are being asked to participate in a study of a new drug, Alirocumab [“study drug”] because you have high cholesterol despite the cholesterol lowering drugs you are currently taking. The study drug is a fully human monoclonal antibody (a type of protein). The study drug is a type of ...
FOURIER - Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease.
Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease
Prevalence of type 2 diabetes in Asia seems to be almost epidemic and establishment of preventive strategy against macrovascular as well as microvascular diseases are warranted because of higher cardiovascular risk in diabetic patients even without history of atherosclerotic cardiovascular diseases. Benefit of lowering low density lipoprotein (LDL) cholesterol down ...
A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes
Type 2 diabetes (T2D) is an increasing global problem, especially in developing countries. T2D is associated with an increased risk of cardiovascular disease (CVD), where hyperglycemia is especially important for microvascular damage. Previous studies in T2D on reduced carbohydrate intake has shown beneficial effects on glycemic control, indicated by reduction ...
The Hellenic Postprandial Lipemia Study (HPLS)
The study aims to recruit 1200 patients that are characterized either as high risk or very-high risk for Coronary Heart Disease. It is assumed that an equal number of high risk and very high risk patients will be included in the study. Patients will be invited to participate in the ...
Dyslipidemia and Diabetic Retinopathy
The purpose of this study is to determine if the reparative cells of blood vessels, called endothelial progenitor cells (EPC's) are defective in people with diabetes. Diabetic retinopathy (DR) is an eye disease related to diabetes. It can cause blurred vision and possible bleeding in the blood vessels in the ...
A Randomized Prospective Open Label Active Control Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
To investigate the therapeutic effect of ezetimibe on nonalcoholic fatty liver disease, the effect of rosuvastatin 5mg monotherapy and rosuvastatin 5mg / ezetimibe 10mg combination therapy n patients with hyperlipidemia and fatty liver will be compared and analyzed. This study included a total of 70 patients (35 per subgroup) for ...
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/amlodipine/rosuvastatin treatment group to the fimasartan/amlodipine treatment group and the fimasartan/rosuvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia who fail to respond to the fimasartan monotherapy.
